{
    "organizations": [],
    "uuid": "862b858820a8ad705cf439fb698c62a9411805df",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-deinove-takes-on-a-whole-new-dimen/brief-deinove-takes-on-a-whole-new-dimension-with-the-acquisition-of-morphochems-clinical-stage-antibiotic-compound-idUSASO00038Z",
    "ord_in_thread": 0,
    "title": "BRIEF-Deinove Takes On A Whole New Dimension With The Acquisition Of Morphochem's Clinical Stage Antibiotic Compound",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 13 (Reuters) - Deinove SA:\n* DEINOVE TAKES ON A WHOLE NEW DIMENSION WITH THE ACQUISITION OF MORPHOCHEM’S CLINICAL-STAGE ANTIBIOTIC COMPOUND\n* DEINOVE SA- ANNOUNCES ACQUISITION, THROUGH A CONTRIBUTION-IN-KIND TRANSACTION, OF ENTIRE CAPITAL OF AUSTRIAN COMPANY BIOVERTIS AG\n* DEINOVE SA- BIOVERTIS OWNS ENTIRE CAPITAL OF GERMAN COMPANY MORPHOCHEM, WITH LATTER DEVELOPING CLINICAL-STAGE ANTIBIOTIC COMPOUND “MCB3837” Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-13T12:35:00.000+03:00",
    "crawled": "2018-04-14T13:37:48.008+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "deinove",
        "sa",
        "deinove",
        "take",
        "whole",
        "new",
        "dimension",
        "acquisition",
        "morphochem",
        "antibiotic",
        "compound",
        "deinove",
        "announces",
        "acquisition",
        "transaction",
        "entire",
        "capital",
        "austrian",
        "company",
        "biovertis",
        "ag",
        "deinove",
        "biovertis",
        "owns",
        "entire",
        "capital",
        "german",
        "company",
        "morphochem",
        "latter",
        "developing",
        "antibiotic",
        "compound",
        "mcb3837",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}